Patents by Inventor Zhili Xin

Zhili Xin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS
    Publication number: 20150203493
    Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
    Type: Application
    Filed: August 5, 2013
    Publication date: July 23, 2015
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Kevin Guckian, Gnanasambandam Kumaravel, Bin Ma, Lihong Sun, Zhili Xin, Lei Zhang
  • COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS
    Publication number: 20150183741
    Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
    Type: Application
    Filed: August 5, 2013
    Publication date: July 2, 2015
    Inventors: Kevin Guckian, Gnanasambandam Kumaravel, Bin Ma, Lihong Sun, Zhili Xin, Lei Zhang
  • Compounds useful as Raf kinase inhibitors
    Patent number: 8802657
    Abstract: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: August 12, 2014
    Assignees: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Jennifer Cossrow, Bing Guan, John Howard Jones, Gnanasambandam Kumaravel, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
    Patent number: 8586594
    Abstract: Compounds of formula (I), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Pharmaceutical compositions of formula (I) and related methods for treating or preventing metabolic diseases or conditions.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: November 19, 2013
    Assignee: AbbVie Inc.
    Inventors: Andrew J. Souers, Ju Gao, Todd M. Hansen, Rajesh R. Iyengar, Philip R. Kym, Bo Liu, Zhonghua Pei, Vince S. Yeh, Gang Zhao, Zhili Xin
  • Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
    Patent number: 8557828
    Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, and R3, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: October 15, 2013
    Assignee: AbbVie Inc.
    Inventors: Gang Liu, Zhili Xin, Philip R. Kym, Andrew J. Souers
  • Compounds useful as Raf kinase inhibitors
    Patent number: 8293752
    Abstract: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: October 23, 2012
    Assignees: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Weirong Chen, Jennifer Cossrow, Lloyd Franklin, Bing Guan, John Howard Jones, Gnanasambandam Kumaravel, Benjamin Lane, Adam Littke, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME
    Publication number: 20120238581
    Abstract: Compounds of formula (I), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Pharmaceutical compositions of formula (I) and related methods for treating or preventing metabolic diseases or conditions.
    Type: Application
    Filed: May 31, 2012
    Publication date: September 20, 2012
    Inventors: Andrew J. Souers, Ju Gao, Todd M. Hasen, Rajesh R. Iyengar, Philip R. Kym, Bo Liu, Zhonghua Pei, Vince S. Yeh, Gang Zhao, Zhili Xin
  • Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
    Patent number: 8202878
    Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, a pharmaceutical composition of formula (I), and related methods for treating or preventing metabolic diseases or conditions.
    Type: Grant
    Filed: November 29, 2007
    Date of Patent: June 19, 2012
    Assignee: Abbott Laboratories
    Inventors: Andrew J. Souers, Ju Gao, Todd M. Hansen, Rajesh R. Iyengar, Philip R. Kym, Bo Liu, Zhonghua Pei, Vince S. Yeh, Gang Zhao, Zhili Xin
  • HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
    Publication number: 20120040951
    Abstract: The present invention provides compounds of formula (I) useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    Type: Application
    Filed: December 30, 2009
    Publication date: February 16, 2012
    Inventors: Claudio Chuaqui, Jennifer Cossrow, James Dowling, Bing Guan, Michael Hoemann, Alexey Ishchenko, John Howard Jones, Lori Kabigting, Gnanasambandam Kumaravel, Hairuo Peng, Noel Powell, Brian Raimundo, Hiroko Tanaka, Kurt van Vloten, Jeffrey Vessels, Zhili Xin
  • INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME
    Publication number: 20120041003
    Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, and R3, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
    Type: Application
    Filed: October 20, 2011
    Publication date: February 16, 2012
    Applicant: Abbott Laboratories
    Inventors: Gang Liu, Zhili Xin, Philip R. Kym, Andrew J. Souers
  • Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
    Patent number: 8076344
    Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, and R3, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: December 13, 2011
    Assignee: Abbott Laboratories
    Inventors: Gang Liu, Zhili Xin, Philip R. Kym, Andrew J. Souers
  • Heterocyclic compounds useful as RAF kinase inhibitors
    Patent number: 7968536
    Abstract: The present invention provides compounds useful as inhibitors of protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: June 28, 2011
    Assignees: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Jennifer Cossrow, Bing Guan, Alexey Ishchenko, John Howard Jones, Gnanasambandam Kumaravel, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • Inhibitors of c-jun -terminal kinases
    Patent number: 7888374
    Abstract: The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.
    Type: Grant
    Filed: January 23, 2006
    Date of Patent: February 15, 2011
    Assignee: Abbott Laboratories
    Inventors: Gang Liu, Hing L. Sham, Bruce G. Szczepankiewicz, Zhili Xin, Hongyu Zhao, Michael D. Serby, Bo Liu, Mei Liu
  • COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
    Publication number: 20090036419
    Abstract: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    Type: Application
    Filed: June 30, 2008
    Publication date: February 5, 2009
    Applicant: Sunesis Pharmaceuticals, Inc.
    Inventors: Weirong Chen, Jennifer Cossrow, Lloyd Franklin, Bing Guan, John Howard Jones, Gnanasambandam Kumaravel, Benjamin Lane, Adam Littke, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • Heterocyclic Compounds Useful as RAF Kinase Inhibitors
    Publication number: 20090005359
    Abstract: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    Type: Application
    Filed: June 30, 2008
    Publication date: January 1, 2009
    Applicant: Sunesis Pharmaceuticals, Inc
    Inventors: Jennifer Cossrow, Bing Guan, Alexey Ishchenko, John Howard Jones, Gnanasambandam Kumaravel, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme
    Publication number: 20080293713
    Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, and R3, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
    Type: Application
    Filed: April 30, 2008
    Publication date: November 27, 2008
    Applicant: Abbott Laboratories
    Inventors: Gang Liu, Zhili Xin, Philip R. Kym, Andrew J. Souers
  • Protein-tyrosine phosphatase inhibitors and uses thereof
    Patent number: 7169797
    Abstract: The present invention is directed to compounds of formula (I), or a pharmaceutically suitable salt or prodrug thereof, which are useful for the selective inhibition of protein tyrosine phosphatase-1B (PTP1B), and are useful for the treatment of disorders caused by overexpressed or altered protein tyrosine phosphatase 1B.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: January 30, 2007
    Assignee: Abbott Laboratories
    Inventors: Zhili Xin, Gang Liu, Zhonghua Pei, Bruce G. Szczepankiewicz, Michael D. Serby, Hongyu Zhao
  • Thienopyridones as AMPK activators for the treatment of diabetes and obesity
    Publication number: 20060287356
    Abstract: The present invention relates to compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, and obesity.
    Type: Application
    Filed: August 24, 2006
    Publication date: December 21, 2006
    Inventors: Rajesh Iyengar, Andrew Judd, Gang Zhao, Philip Kym, Hing Sham, Yugui Gu, Gang Liu, Mei Liu, Hongyu Zhao, Richard Clark, Ernst Frevert, Barbara Cool, Tianyuan Zhang, Robert Keyes, Todd Hansen, Zhili Xin
  • Thienopyridones as AMPK activators for the treatment of diabetes and obesity
    Patent number: 7119205
    Abstract: The present invention relates to compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, and obesity.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: October 10, 2006
    Assignee: Abbott Laboratories
    Inventors: Rajesh R. Iyengar, Andrew S. Judd, Gang Zhao, Philip R. Kym, Hing L. Sham, Yugui Gu, Gang Liu, Mei Liu, Hongyu Zhao, Richard F. Clark, Ernst U. Frevert, Barbara L. Cool, Tianyuan Zhang, Robert F. Keyes, Todd M. Hansen, Zhili Xin
  • Tetraline derivatives as ghrelin receptor modulators
    Patent number: 7115767
    Abstract: The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: October 3, 2006
    Assignee: Abbott Laboratories
    Inventors: Bo Liu, Gang Liu, Lissa T. J. Nelson, Jyoti R. Patel, Hing L. Sham, Zhili Xin, Hongyu Zhao